J. Gillen

430 total citations
17 papers, 158 citations indexed

About

J. Gillen is a scholar working on Oncology, Reproductive Medicine and Cancer Research. According to data from OpenAlex, J. Gillen has authored 17 papers receiving a total of 158 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 8 papers in Reproductive Medicine and 8 papers in Cancer Research. Recurrent topics in J. Gillen's work include Ovarian cancer diagnosis and treatment (8 papers), BRCA gene mutations in cancer (5 papers) and Cancer Genomics and Diagnostics (5 papers). J. Gillen is often cited by papers focused on Ovarian cancer diagnosis and treatment (8 papers), BRCA gene mutations in cancer (5 papers) and Cancer Genomics and Diagnostics (5 papers). J. Gillen collaborates with scholars based in United States. J. Gillen's co-authors include Kathleen N. Moore, Debra L. Richardson, B. Schellenberg, H. Schmidt‐Gayk, Klaus‐Henning Krause, Peter Berlit, Yair Lotan, Alana Christie, Xian‐Jin Xie and Kai Ding and has published in prestigious journals such as Gynecologic Oncology, The American Surgeon and Current Oncology Reports.

In The Last Decade

J. Gillen

17 papers receiving 156 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Gillen United States 6 43 31 25 25 20 17 158
Maren Keller Germany 9 52 1.2× 46 1.5× 30 1.2× 51 2.0× 13 0.7× 33 213
Dan-Arin Silasi United States 7 45 1.0× 82 2.6× 13 0.5× 38 1.5× 21 1.1× 7 190
Melanie Polin United States 6 79 1.8× 32 1.0× 7 0.3× 24 1.0× 13 0.7× 11 201
Naïri Tchrakian Canada 7 36 0.8× 50 1.6× 6 0.2× 20 0.8× 18 0.9× 12 145
Anna Linder Sweden 10 69 1.6× 57 1.8× 13 0.5× 10 0.4× 10 0.5× 19 214
Eleonora D’Armiento Italy 11 60 1.4× 60 1.9× 56 2.2× 10 0.4× 16 0.8× 17 308
Roya Behrouzi United Kingdom 7 46 1.1× 31 1.0× 4 0.2× 39 1.6× 7 0.3× 11 184
Katharina Leitner Austria 7 51 1.2× 42 1.4× 5 0.2× 35 1.4× 10 0.5× 20 149
Wenying Zheng China 10 173 4.0× 31 1.0× 10 0.4× 28 1.1× 15 0.8× 15 298
Simeng Gu China 9 114 2.7× 53 1.7× 9 0.4× 9 0.4× 15 0.8× 30 274

Countries citing papers authored by J. Gillen

Since Specialization
Citations

This map shows the geographic impact of J. Gillen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Gillen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Gillen more than expected).

Fields of papers citing papers by J. Gillen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Gillen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Gillen. The network helps show where J. Gillen may publish in the future.

Co-authorship network of co-authors of J. Gillen

This figure shows the co-authorship network connecting the top 25 collaborators of J. Gillen. A scholar is included among the top collaborators of J. Gillen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Gillen. J. Gillen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
John, Catherine, Abigail Fong, Rodrigo F. Alban, et al.. (2021). Breast cancer surveillance following ovarian cancer in BRCA mutation carriers. Gynecologic Oncology. 164(1). 202–207. 5 indexed citations
3.
Gillen, J., Austin Miller, Katherine M. Bell‐McGuinn, et al.. (2021). Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study. Gynecologic Oncology. 161(2). 512–515. 5 indexed citations
4.
Gillen, J., et al.. (2020). Association of financial assistance programs and time to completion of therapy in women receiving chemoradiation for cervical cancer. Gynecologic Oncology Reports. 34. 100660–100660. 4 indexed citations
5.
Fong, Abigail, Ilana Cass, Catherine John, et al.. (2020). Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers. The American Surgeon. 86(10). 1243–1247. 3 indexed citations
6.
Gillen, J., Debra L. Richardson, & Kathleen N. Moore. (2019). Angiopoietin-1 and Angiopoietin-2 Inhibitors: Clinical Development. Current Oncology Reports. 21(3). 22–22. 26 indexed citations
7.
Gillen, J., Kathryn Mills, Josef Dvořák, et al.. (2019). Imaging biomarkers of adiposity and sarcopenia as potential predictors for overall survival among patients with endometrial cancer treated with bevacizumab. Gynecologic Oncology Reports. 30. 100502–100502. 15 indexed citations
8.
Gillen, J., et al.. (2019). Impact of financial assistance programs on time to completion of therapy in women receiving chemoradiation for cervical cancer. Gynecologic Oncology. 154. 6–7. 1 indexed citations
9.
10.
Gillen, J., Camille C. Gunderson, R. Ruskin, et al.. (2017). Contribution of age to clinical trial enrollment and tolerance with ovarian cancer. Gynecologic Oncology. 145(1). 32–36. 8 indexed citations
11.
Ruskin, R., et al.. (2017). Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women. Gynecologic Oncology. 146(2). 268–272. 4 indexed citations
12.
Moore, Kathleen N., et al.. (2017). Factors influencing clinical trial enrollment among ovarian cancer patients. Gynecologic Oncology. 146(3). 465–469. 9 indexed citations
13.
Gillen, J., Kathryn Mills, Josef Dvořák, et al.. (2017). Imaging Biomarkers of Adiposity and Sarcopenia as Potential Predictors for Overall Survival Among Patients with Endometrial Cancer Treated with Bevacizumab. Gynecologic Oncology. 147(1). 198–199. 3 indexed citations
14.
Gillen, J., et al.. (2016). Contribution of age to clinical trial enrollment and tolerance with ovarian cancer. Gynecologic Oncology. 141. 128–128. 1 indexed citations
15.
Ruskin, R., et al.. (2016). Factors influencing clinical trial enrollment among ovarian cancer patients. Gynecologic Oncology. 141. 124–125. 1 indexed citations
16.
Gayed, Bishoy A., J. Gillen, Alana Christie, et al.. (2015). Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma. BMC Urology. 15(1). 24–24. 35 indexed citations
17.
Krause, Klaus‐Henning, et al.. (1982). Vitamin status in patients on chronic anticonvulsant therapy.. PubMed. 52(4). 375–85. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maren Keller Breakdown of academic impact, for papers by Dan-Arin Silasi Breakdown of academic impact, for papers by Melanie Polin Breakdown of academic impact, for papers by Naïri Tchrakian Breakdown of academic impact, for papers by Anna Linder Breakdown of academic impact, for papers by Eleonora D’Armiento Breakdown of academic impact, for papers by Roya Behrouzi Breakdown of academic impact, for papers by Katharina Leitner Breakdown of academic impact, for papers by Wenying Zheng Breakdown of academic impact, for papers by Simeng Gu
Rankless by CCL
2026